Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) is scheduled to be releasing its earnings data after the market closes on Thursday, August 8th. Analysts expect Xenon Pharmaceuticals to post earnings of ($0.72) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.07. The business had revenue of $1.00 million for the quarter. During the same quarter in the prior year, the business posted ($0.63) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year. On average, analysts expect Xenon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Xenon Pharmaceuticals Price Performance
Shares of Xenon Pharmaceuticals stock traded up $1.09 during trading on Tuesday, hitting $42.57. 90,921 shares of the company’s stock traded hands, compared to its average volume of 405,885. The firm’s fifty day moving average price is $39.53 and its 200 day moving average price is $42.37. Xenon Pharmaceuticals has a twelve month low of $27.99 and a twelve month high of $50.99. The company has a market cap of $3.21 billion, a PE ratio of -15.45 and a beta of 1.26.
Analyst Ratings Changes
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Recommended Stories
- Five stocks we like better than Xenon Pharmaceuticals
- What is a Secondary Public Offering? What Investors Need to Know
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.